News

All news
  • New labeling rules or who will pay for a broken system!

    Failures in the labeling system lead to a shortage of drugs on the market. Hundreds of millions of packages of medicines have accumulated in warehouses and quarantine zones of the distribution chain. To avoid a collapse, the Government has simplified the procedure for working with the drug monitoring system. The new regime will operate until the full readiness of the industry participants. The changes apply to all drugs, both produced in the country and imported into the Russian Federation, with the exception of drugs from category 12 high-cost nosologies. The document contains simplified mechanisms and a notification character when working with the system. According to the regulator, the industry is to blame for the current situation, and not the operator, which did not prepare the system for work under load.

  • Results of the conference "State regulation and the Russian pharmaceutical industry: continuation of the dialogue"

    The XII scientific-practical conference "State regulation and the Russian pharmaceutical industry: continuation of the dialogue", organized by the Association of Russian pharmaceutical manufacturers and the National Research Institute of Public Health named after N.A. Semashko. The event was attended by representatives of regulatory authorities, expert organizations, pharmaceutical companies, medical communities and patient organizations.

  • Pitfalls on the way to a single pharmaceutical market at the conference "Government regulation and the Russian pharmaceutical industry: continuation of the dialogue"

    2020 was the year of bringing the drug dossier in correspondence with the unified rules of the EAEU, but the COVID-19 pandemic intervened in this process. In the union states, GMP inspection of sites has been temporarily suspended, and in Russia remote methods of checking good manufacturing practices are being introduced. These are not the only pitfalls on the way to a unified pharmaceutical market. The main issues of law enforcement that require priority attention will be discussed by representatives of the authorized bodies of the countries of the Eurasian Economic Union with leading experts of the pharmaceutical industry at the conference "State regulation and the Russian pharmaceutical industry: continuation of the dialogue" on October 27 online.

  • Prospects for pilot projects on the drug supply at the conference "State regulation and the pharmaceutical industry: continuation of the dialogue"

    The pandemic has contributed to the rise in deaths from cardiovascular diseases. In the first half of 2020, almost 40 thousand people died from acute coronary syndrome, and more than 220 thousand people died from coronary heart disease. For many years, cardiovascular disease has been at the top of the mortality statistics rating. Pilot drug reimbursement projects are intended to reduce this high rate; their start was scheduled for July 2020. However, COVID-19 has made its own adjustments.

  • It is pointless to continue doing the same and wait for different results

    The pharmaceutical industry is at the crossroads of interests between healthcare and patients. Its development is one of the state priorities, therefore it is very important to maintain a balance of interests in providing the population with affordable drugs. Today there are many sensitive topics that need to be considered from different points of view in order to make the right decision. The challenges facing the market were discussed by industry experts at a round table in the amber capital and online on September 25 within the framework of the Partnership "Medicines of Russia - for an interdisciplinary dialogue".

  • Journalists ask questions about the first drugs registered for retail sale for the new coronavirus infection and their high price.

    In recent days, the Association of Russian Pharmaceutical Manufacturers has received inquiries from the media. Journalists ask questions about the first drugs registered for retail sale for the new coronavirus infection and their high price.

  • There are only a few days left before the start of the Partnering "Medicines of Russia - towards an interdisciplinary dialogue".

    On September 25, a lively discussion of experts from the pharmaceutical industry and medicine with representatives of the legislative and executive authorities will take place on the most pressing issues of drug supply to the population in online and offline formats. The forum is held in a mixed format: offline on the site of the Kaliningrad region and online on the zoom platform and YouTube channel. Registration is required. Access strictly by link, which will be sent to you automatically in response to the application. This is due to technical capabilities. To date, about 150 people have applied for participation. Hurry up and register today for an interdisciplinary consultation. We value your opinion in matters of drug supply to the population.

Projects

All projects

Membership of ARFP in the Organizations

Russian Union of Industrialists
and Entrepreneurs (RSPP)

rspp.ru

Chamber of Commerce and Industry (CCI)
of the Russian Federation

tpprf.ru

Awards of Association

Partners of association